289 related articles for article (PubMed ID: 3744945)
1. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Zeman EM; Hirst VK; Lemmon MJ; Brown JM
Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
[TBL] [Abstract][Full Text] [Related]
3. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
Zeman EM; Lemmon MJ; Brown JM
Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
6. Pre- and post-irradiation radiosensitization by SR 4233.
Zeman EM; Brown JM
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
8. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Zhang M; Stevens G
Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
[TBL] [Abstract][Full Text] [Related]
9. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
10. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
Minchinton AI; Lemmon MJ; Tracy M; Pollart DJ; Martinez AP; Tosto LM; Brown JM
Int J Radiat Oncol Biol Phys; 1992; 22(4):701-5. PubMed ID: 1544841
[TBL] [Abstract][Full Text] [Related]
11. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
12. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
13. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for benzotriazine di-N-oxides.
Zeman EM; Baker MA; Lemmon MJ; Pearson CI; Adams JA; Brown JM; Lee WW; Tracy M
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):977-81. PubMed ID: 2703405
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model.
Baas P; Oppelaar H; Stavenuiter M; van Zandwijk N; Stewart FA
Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):665-70. PubMed ID: 8226162
[TBL] [Abstract][Full Text] [Related]
16. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Herman TS; Teicher BA; Coleman CN
Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
[TBL] [Abstract][Full Text] [Related]
17. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Lartigau E; Stern S; Guichard M
Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.
Hanauske AR; Ross M; Degen D; Hilsenbeck SG; Von Hoff DD
Eur J Cancer; 1993; 29A(3):423-5. PubMed ID: 8398345
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
Minchinton AI; Brown JM
Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
[TBL] [Abstract][Full Text] [Related]
20. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
